Table 1. Case reports of new onset psoriasis following treatment for rheumatoid arthritis with anti-tumour necrosis factor (TNF) therapy.
Patient | Reference | Age/sex | Affected areas | Diagnosis | Treatment | Latency, months |
1 | Beuthien et al10 | 63F | Injection site (thigh), palms and soles | Papulopustular exanthaema | ADA | 3 |
2 | Dereure et al11 | 47F | Anterior aspects of legs | Psoriasis | INF | 2 |
3 | Dereure et al11 | 55F | Palms, soles, umbilicus, ankles wrists and buttocks | Psoriasis | ETA | 3 |
4 | Flendrie et al12 | – | Hands and feet | Psoriasis/psoriaform eruption | ADA | 9 |
5 | Flendrie et al12 | – | Lower legs | Psoriasis/psoriaform eruption | ADA | 48 |
6 | Flendrie et al12 | – | Arms and legs | Psoriasis/psoriaform eruption | ADA | 16 |
7 | Grinblat et al13 | 37F | Scalp, arms and legs | Psoriasis | INF | <1 week |
8 | Sfikakis et al14 | 65F | Palms, soles, elbows, arms and thighs | Psoriasis | ADA | 9 |
9 | Sfikakis et al14 | 48F | Soles, elbows, lower legs | Psoriatic plaques | ETA | 7 |
10 | Kary et al15 | 41F | Palms, soles, legs and arms | Psoriasis vulgaris | ADA | 14–15 |
11 | Kary et al15 | 65F | Limbs | Psoriasis vulgaris | ADA | 4 days |
12 | Kary et al15 | 38M | Limbs and abdomen (Had family sister) | Psoriasis vulgaris | INF | 3 |
13 | Kary et al15 | 67F | Palms, arms, legs and scalp (Had family brother) | Psoriasis pustulosa | ADA | 5 |
14 | Kary et al15 | 49F | Legs and soles of feet (pre-existing but asymptomatic) | Psoriasis pustulosa | INF | 8 |
15 | Kary et al15 | 49F | Legs and arms (pre-existing but asymptomatic for 15 years) | Psoriasis pustulosa | ETA | 1 |
16 | Kary et al15 | 63F | Extremities and trunk | Psoriasis vulgaris | ETA | 2 |
17 | Sari et al16 | 30F | Scalp, elbows, abdomen and lower back | Psoriasis | ETA | 2 |
18 | Goncalves et al17 | 61F | Hands and feet | Plaque psoriasis | INF | 14 |
19 | Aslanidis et al18 | 64F | Elbows, neck and scalp | Psoriasisiform dermatitis | ADA | 3 |
20 | Cohen et al19 | 70F | Pubis, umbilicus, legs | Psoriasis | INF | 41 |
21 | Cohen et al19 | 63F | Legs, arms | Psoriasis | ETA | 10 |
22 | de Gannes et al20 | 41F | Heel and palm | Palmoplantar psoriasis | ETA | 26 |
23 | de Gannes et al20 | 53F | Elbows | Plaque psoriasis | ETA | 17 |
24 | de Gannes et al20 | 66F | Scalp, arms, chest and neck | Plaque and guttate psoriasis | ETA | 4 |
25 | de Gannes et al20 | 51M | Elbows | Psoriasis | ETA | 12 |
26 | de Gannes et al20 | 48F | Arms and trunk | Papulosquamous eruption | ETA | 3 |
27 | de Gannes et al20 | 41F | Scalp, thigh and thumb | Palmoplantar pustular psoriasis | INF | 2 |
28 | de Gannes et al20 | 52F | Palmoplantar pustular psoriasis | Palmoplantar pustular psoriasis | INF | 24 |
29 | de Gannes et al20 | 78F | Lesions on shins | Thick surface keratin with focal parakeratosis | INF | 2 |
30 | de Gannes et al20 | 56M | Palms, soles, legs | Pustular psoriasis | ADA | 62 |
31 | de Gannes et al20 | 50M | Trunk, shins and arms | Psoriasis | INF | 12 |
32 | de Gannes et al20 | 55F | Palms, soles and ankles | Plaque and pustular psoriasis | ADA | 36 |
33 | de Gannes et al20 | 49M | Palms and soles | Pustular psoriasis | ADA | 5 |
34 | de Gannes et al20 | 37F | Plantar surfaces | Plaque psoriasis with subsequent pustules | ETA | 24 |
35 | Ubriani et al21 | 65F | Legs, trunk and extremities | Psoriasis | INF | 48 |
36 | Ubriani et al21 | 45F | Palmoplantar pustulosis | Palmoplantar pustulosis | ADA | 1 |
37 | Starmans-Kool et al22 | 62F | Hands and feet. Swollen hands, knees | Palmoplantar pustulosis | INF | 5th Infusion |
38 | Michaelsson et al23 | 62F | Palmoplantar pustulosis with lesions on legs and arms | Palmoplantar pustulosis & pustular psoriasis | INF | 2 weeks |
39 | Michaelsson et al23 | 50F | Palmoplantar pustulosis with lesions on extremities | Palmoplantar pustulosis | INF | 1.5 |
40 | Roux et al24 | 42F | Psoriatic palmoplantaris pustulosis | Psoriatic palmoplantaris pustulosis | INF | 1.5 |
41 | Roux et al24 | 32F | Plantaris pustulosis with lesions on legs, arms and trunk | Psoriatic palmoplantaris pustulosis & diffuse erythaematosquamous lesions | INF | 7 |
ADA, adalimumab; ETA, etanercept; INF, infliximab.